Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides androgens, there is evidence that thyroid hormone thyroxine (T4) and its active form 3,5,3'-triiodo-L-thyronine (T3) are involved in the progression of PCa. Epidemiologic evidences show a higher incidence of PCa in men with elevated thyroid hormone levels. The thyroid hormone binding protein μ-Crystallin (CRYM) mediates intracellular thyroid hormone action by sequestering T3 and blocks its binding to cognate receptors (TRα/TRβ) in target tissues. We show in our study that low CRYM expression levels in PCa patients are associated with early biochemical recurrence and poor prognosis. Moreover, we found a disease stage-specific expression of CRYM in PCa. CRYM counteracted thyroid and androgen signaling and blocked intracellular choline uptake. CRYM inversely correlated with [18F]fluoromethylcholine (FMC) levels in positron emission tomography/magnetic resonance imaging of PCa patients. Our data suggest CRYM as a novel antagonist of T3- and androgen-mediated signaling in PCa. The role of CRYM could therefore be an essential control mechanism for the prevention of aggressive PCa growth.
- MeSH
- androgenní receptory genetika metabolismus MeSH
- buňky PC-3 MeSH
- cholin aplikace a dávkování analogy a deriváty MeSH
- čipová analýza tkání MeSH
- down regulace * MeSH
- kohortové studie MeSH
- krystaliny genetika metabolismus MeSH
- lidé MeSH
- metabolomika MeSH
- nádorové buněčné linie MeSH
- nádory prostaty diagnostické zobrazování genetika metabolismus patologie MeSH
- PET/CT MeSH
- prognóza MeSH
- receptory thyreoidních hormonů genetika MeSH
- regulace genové exprese u nádorů MeSH
- sekvenční analýza RNA MeSH
- signální transdukce * MeSH
- staging nádorů MeSH
- stanovení celkové genové exprese MeSH
- trijodthyronin antagonisté a inhibitory metabolismus MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: ECCO essential requirements for quality cancer care (ERQCC) are checklists and explanations of organisation and actions that are necessary to give high-quality care to patients who have a specific type of cancer. They are written by European experts representing all disciplines involved in cancer care. ERQCC papers give oncology teams, patients, policymakers and managers an overview of the elements needed in any healthcare system to provide high quality of care throughout the patient journey. References are made to clinical guidelines and other resources where appropriate, and the focus is on care in Europe. OESOPHAGEAL AND GASTRIC: ESSENTIAL REQUIREMENTS FOR QUALITY CARE: CONCLUSION: Taken together, the information presented in this paper provides a comprehensive description of the essential requirements for establishing a high-quality OG cancer service. The ERQCC expert group is aware that it is not possible to propose a 'one size fits all' system for all countries, but urges that access to multidisciplinary units or centres must be guaranteed for all those with OG cancer.
- MeSH
- kvalita zdravotní péče MeSH
- lékařská onkologie metody organizace a řízení normy MeSH
- lidé MeSH
- nádory jícnu terapie MeSH
- nádory žaludku terapie MeSH
- poskytování zdravotní péče metody organizace a řízení normy MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Evropa MeSH
